A study by Pereira et al. demonstrated a correlation between bone FGF23 expression by immunohistochemistry and parameters of mineralization in pediatric and young adult patients with CKD stages 2–5 [23], underscoring the importance of evaluating bone FGF23 in association with histomorphometry. This evidence concerns the gene FGF23 and chronic kidney disease.